Company intelligence / Profile preview

Nupathways

Evanston, Illinois, United States

Ownership: Private
Development stage: Other

Overview

NuPathways is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for neuropsychiatric and neurological disorders. The company's primary focus is on modulating the N-methyl-D-aspartate (NMDA) receptor to treat conditions such as treatment-resistant depression (TRD). Its lead program, NPW-101, is an orally bioavailable NMDA receptor functional partial agonist designed to trigger rapid and sustained antidepressant effects. NuPathways was founded by the scientific team behind Naurex and Aptinyx, bringing extensive experience in synaptic plasticity and CNS drug development.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

ULTRACUR-PRO

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Nupathways.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nupathways.

Explore the full profile